Clinical Trial Update: Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing bortezomib-melphalan conditioning vs melphalan for frontline transplant-eligible multiple myeloma patients; study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib-melphalan conditioning regimen
• Melphalan (Melphalan)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED